<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385810</url>
  </required_header>
  <id_info>
    <org_study_id>JDS_2020_13</org_study_id>
    <nct_id>NCT04385810</nct_id>
  </id_info>
  <brief_title>Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19</brief_title>
  <acronym>DOCOV</acronym>
  <official_title>Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of patients with SARS-CoV2 in respiratory distress can expose to corneal or
      retinal lesions induced by the stay in intensive care.

      Examination by ophthalmologists would make it possible to detect the most of the
      ophthalmologic problems known in intensive care and to provide an early, preventive or
      curative therapeutic response when possible, in order to avoid irreversible visual loss.

      The object of the research is to assess the presence and the importance of surface
      ophthalmologic lesions, the presence and the importance of retinal or optic nerve lesions, in
      order to improve the monitoring and primary prevention of this population
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ophthalmologic exam</intervention_name>
    <description>Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital</description>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient SARS-CoV2 positive (RT-PCR or chest scanner)

          -  hospitalized in intensive care

        Exclusion Criteria:

          -  traumatic lesion of the face or any other condition preventing any ophthalmological
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Michel DEVYS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Adolphe de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Am√©lie YAVCHITZ, MD</last_name>
    <phone>01 48 03 64 54</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie STEPHAN, MD</last_name>
    <email>sstephan@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie STEPHAN, MD</last_name>
      <email>sstephan@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ophthalmological lesions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

